Tags

Type your tag names separated by a space and hit enter

[Piperazinyl estrone prevents bone loss in ovariectomized rats].
Yao Xue Xue Bao. 2003 Mar; 38(3):161-4.YX

Abstract

AIM

To determine the effect of piperazinyl estrone, a new estrogen derivative, on bone turnover, bone mass and uteri in ovariectomized rats.

METHODS

Female Sprague-Dawley rats were ovariectomized (OVX) or sham operated (sham) at the age of 3 months and treated with estrone (E) at 0.75 mg.kg-1.d-1, or with piperazinyl estrone (P-E) at 1 or 10 mg.kg-1.d-1, orally, for 3 months. At the time of death, the uterine weight was measured. Bone histomorphometric analysis of proximal tibial metaphyses (PTM) was performed in undecalcified sections.

RESULTS

Bone histomorphometric data showed that the percent trabecular area (% Tb.Ar) of OVX rats with bone high turnover was significantly decreased. The uteri were atrophied. The percent trabecular area (% Tb.Ar) of estrone treated group was increased in decreasing bone turnover manner. But the size and weight of uteri in this group were increased vs OVX group. The bone loss induced by OVX was preserved by P-E treatment, but the mechanism of maintaining bone is different from that of E-treated rats. P-E treatment in low dose did not decrease any bone formation indices, such as percent labeling perimeter, bone formation rate per bone volume (BFR/BV), except bone mineral apposition rate (MAR) compared with E-treated group, and maintained them at OVX level. The uteri were found to be in atrophy compared with the match dose (0.75 mg) of E-treated OVX rats. But rats treated with high dose of P-E showed the same change like E-treated group.

CONCLUSION

The finding of this study shows that lower dosage of piperazinyl estrone has effect on preventing the bone losses in OVX rats, while the bone formation and the uterus are not affected, thus supporting the hypothesis that piperazinyl estrone has the potential to prevent postmenopausal bone loss in women with less side effects.

Authors+Show Affiliations

Institute of Biomedical Engineering, West China University of Medical Science, Chengdu 610041, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

12830707

Citation

Li, Qing-nan, et al. "[Piperazinyl Estrone Prevents Bone Loss in Ovariectomized Rats]." Yao Xue Xue Bao = Acta Pharmaceutica Sinica, vol. 38, no. 3, 2003, pp. 161-4.
Li QN, Weng LL, Huang LF, et al. [Piperazinyl estrone prevents bone loss in ovariectomized rats]. Yao Xue Xue Bao. 2003;38(3):161-4.
Li, Q. N., Weng, L. L., Huang, L. F., Hu, B., Chen, H. Q., & Zheng, H. (2003). [Piperazinyl estrone prevents bone loss in ovariectomized rats]. Yao Xue Xue Bao = Acta Pharmaceutica Sinica, 38(3), 161-4.
Li QN, et al. [Piperazinyl Estrone Prevents Bone Loss in Ovariectomized Rats]. Yao Xue Xue Bao. 2003;38(3):161-4. PubMed PMID: 12830707.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Piperazinyl estrone prevents bone loss in ovariectomized rats]. AU - Li,Qing-nan, AU - Weng,Ling-ling, AU - Huang,Lian-fang, AU - Hu,Bin, AU - Chen,Huai-qing, AU - Zheng,Hu, PY - 2003/7/2/pubmed PY - 2004/4/21/medline PY - 2003/7/2/entrez SP - 161 EP - 4 JF - Yao xue xue bao = Acta pharmaceutica Sinica JO - Yao Xue Xue Bao VL - 38 IS - 3 N2 - AIM: To determine the effect of piperazinyl estrone, a new estrogen derivative, on bone turnover, bone mass and uteri in ovariectomized rats. METHODS: Female Sprague-Dawley rats were ovariectomized (OVX) or sham operated (sham) at the age of 3 months and treated with estrone (E) at 0.75 mg.kg-1.d-1, or with piperazinyl estrone (P-E) at 1 or 10 mg.kg-1.d-1, orally, for 3 months. At the time of death, the uterine weight was measured. Bone histomorphometric analysis of proximal tibial metaphyses (PTM) was performed in undecalcified sections. RESULTS: Bone histomorphometric data showed that the percent trabecular area (% Tb.Ar) of OVX rats with bone high turnover was significantly decreased. The uteri were atrophied. The percent trabecular area (% Tb.Ar) of estrone treated group was increased in decreasing bone turnover manner. But the size and weight of uteri in this group were increased vs OVX group. The bone loss induced by OVX was preserved by P-E treatment, but the mechanism of maintaining bone is different from that of E-treated rats. P-E treatment in low dose did not decrease any bone formation indices, such as percent labeling perimeter, bone formation rate per bone volume (BFR/BV), except bone mineral apposition rate (MAR) compared with E-treated group, and maintained them at OVX level. The uteri were found to be in atrophy compared with the match dose (0.75 mg) of E-treated OVX rats. But rats treated with high dose of P-E showed the same change like E-treated group. CONCLUSION: The finding of this study shows that lower dosage of piperazinyl estrone has effect on preventing the bone losses in OVX rats, while the bone formation and the uterus are not affected, thus supporting the hypothesis that piperazinyl estrone has the potential to prevent postmenopausal bone loss in women with less side effects. SN - 0513-4870 UR - https://www.unboundmedicine.com/medline/citation/12830707/[Piperazinyl_estrone_prevents_bone_loss_in_ovariectomized_rats]_ L2 - https://medlineplus.gov/osteoporosis.html DB - PRIME DP - Unbound Medicine ER -